Rigel Pharmaceuticals Inc RIGL
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-11-29 |
| Shares Out. | 18,500,000 |
| Website | rigel.com/ ↗ |
| Phone | 13025814070 |
| Employees | 174 |
| Revenue | $58.8M |
| Gross Profit | $54.2M |
| Net Income | $8.7M |
| Free Cash Flow | $79.3M |
| Total Assets | $504.6M |
| Total Liabilities | $104.7M |
| Equity | $399.9M |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Rigel Pharmaceuticals Inc is a publicly traded company under the ticker symbol RIGL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)